(18)F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

BACKGROUND: Positron emission tomography (PET) is poised to become a useful imaging modality in staging and evaluating therapeutic responses in patients with metastatic pancreatic cancer (mPC). This analysis from a phase 1/2 study examined the utility of early PET imaging in patients with mPC treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Korn, Ronald L., Von Hoff, Daniel D., Borad, Mitesh J., Renschler, Markus F., McGovern, Desmond, Curtis Bay, R., Ramanathan, Ramesh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543580/
https://www.ncbi.nlm.nih.gov/pubmed/28774338
http://dx.doi.org/10.1186/s40644-017-0125-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543580/
https://www.ncbi.nlm.nih.gov/pubmed/28774338
http://dx.doi.org/10.1186/s40644-017-0125-5

Ejemplares similares